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Rationale 
Omeprazole is used to treat gastric disorders and is one of the most commonly consumed 
drugs in the western world. It forms several metabolites but is mostly excreted unchanged 
and as 5-hydroxyomeprazole. Since omeprazole is widely prescribed, its excretion from the 
body has a potential environmental effect. After excretion it will enter the wastewater system 
and if not adequately removed during wastewater treatment will be discharged into rivers in 
the wastewater effluent. It is important to consider not only the parent drug but also the main 
metabolite (5-hydroxyomeprazole) and their degradation products to fully understand the fate 
of this drug during wastewater treatment. In order to do this potential degradation products 
need to be determined. 
Methods 
In this study, acid was used to artificially accelerate degradation of omeprazole and 5-
hydroxyomeprazole. A Thermo Scientific Q-Exactive Orbitrap mass spectrometer with 
electrospray ion source was used to determine precursor and product ion data for the 
degradation products.  
Results 
Both starting materials quickly degrade under acidic conditions and the main degradation 
product formed in each case was a re-arranged monomer. Other products formed were doubly 
and singly charged dimer ions with varying numbers of sulphur atoms in the dimer bridge. 
Careful interpretation of the accurate mass, isotope pattern, isotope abundance and product 
ion spectra were used to interpret the data.  
Conclusion 
On comparing the results from omeprazole and 5-hydroxyomeprazole the resultant 
degradants were analogous to each other, differing only by an oxygen atom. This 
investigation determined the degradation products of omeprazole and 5-hydroxyomeprazole 
and proposed structures based on the accurate mass and isotope information. The product 




Omeprazole (Figure 1 (A)) is a proton pump inhibitor used in the treatment of gastric 
disorders and was first marketed in 1989 by Astra Zeneca. It is the most commonly 
prescribed proton pump inhibitor in the western world
1
. In 2015, the highest number of 
community prescriptions in Scotland were for omeprazole, amounting to 3783 kg (including 
esomeprazole) of the active ingredient 
2
. Omeprazole is formulated with an enteric coating to 
prevent degradation in the stomach and ensure the drug reaches the parietal cell intact. Once 
the drug is absorbed through the intestine and into the parietal cell, it is the action of the acid 
excreted in the cell on omeprazole which causes the molecule to re-arrange
3
. The re-arranged 
molecule reacts with the thiol on the acid-producing enzyme
4
 blocking further acid 
production (Scheme 1). Since the acid production is now blocked, the excess omeprazole 
cannot re-arrange and is metabolised prior to excretion. Several metabolites are formed 
however, according to Lagerstrom
5
 the main metabolite detected in urine samples is 5-
hydroxyomeprazole (Figure 2(A)) and small amounts of omeprazole and omeprazole 
sulphone.  
There is currently much interest concerning micro-pollutants in wastewater
6–15 
 though little 
consideration is given to the metabolites or degradation products. In view of omeprazole’s 
widespread use, the resultant degradants for omeprazole and 5-hydroxyomeprazole are of 
great interest as potential environmental pollutants. In order to accelerate the degradation and 
determine the resultant products, omeprazole and 5-hydroxyomeprazole were treated with 
acid and the degradation followed using accurate mass data from a Thermo Scientific Q-
Exactive Orbitrap
16,17
 instrument which is a high resolution mass spectrometer (HRMS). 
HRMS instruments are capable of determining a measured m/z with a high degree of 
certainty, increasing confidence in compound identification and elemental composition 
assignment. The Thermo Scientific Q-Exactive Orbitrap instrument has the capability to 
obtain product ion data (MS
2




Chemicals and Materials 
Optima LCMS grade acetonitrile and formic acid (98%) were purchased from Fisher 
Scientific (Loughborough, UK), omeprazole and 5-hydroxyomeprazole from Fluka 
(Darmstadt, Germany) and ammonium formate solution (10M in water) BioUltra, from 
Sigma-Aldrich (Darmstadt, Germany). An Elga (High Wycombe, UK) Purelab Classic water 
deioniser was used to provide water at 18 M Ώ purity. 
 
LCMS Conditions 
The mass spectrometer was a Thermo Scientific Q-Exactive Orbitrap mass spectrometer, 
fitted with a Dionex Ultimate 3000 RS Pump, Dionex Ultimate 3000 RS autosampler 
(temperature controlled at 10
o
C) and Dionex Ultimate 3000 RS column compartment 
(temperature controlled at 30
o
C) (All from Thermo Fisher Scientific, Hemel Hempstead, 
England).  
The mass spectrometer was fitted with an electrospray ion source (ESI) operated in positive 
ion mode. The nitrogen sheath and auxiliary gas were set at 45 and 10 arbitary units. The 
spray voltage was +3.5 kV and the ion source temperature 300
o
C. 
The full MS experiment scan range was m/z = 100 to 900, with the resolution set at 35000. 
The product ion experiment (MS
2
) was conducted using a mass resolution of 17500. The 
isolation window for the product ion experiment was 4.0 u with a normalised collision energy 
(NCE) of 40 eV. 
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A Waters (Elstree, UK) Atlantis dC18 chromatography column 150 × 2.1 mm, particle size 3 
µm was used for the chromatographic separation. 
The organic solvent was CH3CN (A) and the aqueous (B) was18 M Ώ purity water containing 
10 mmol ammonium formate adjusted to pH 3.5 with formic acid. A gradient elution 
technique was used. The initial conditions were 99% B for 1 minute, dropping to 60% B over 
11 minutes then 1% B over 6 minutes. The gradient was maintained at 1% B before returning 




The software was Tracefinder to operate the chromatography and mass spectrometry system 
and Xcalibur for MS interpretation.  
Prior to commencement of the analysis the instrument was calibrated in positive ion mode 
using Pierce LTQ Velos ESI Positive ion calibration solution, ex Fisher Scientific 
(Loughborough, England). 
 
Acid Treatment of Omeprazole and 5-hydroxyomeprazole 
Separate solutions of omeprazole and 5-hydroxyomeprazole were prepared at a concentration 
of 5000 ng.mL
-1
 in CH3CN/H2O 20/80. These solutions (1 mL) were treated with 100 µL of 
0.2 M HCl in water with mixing. Samples were placed in the autosampler at 10
o
C and 
analysed every 30 minutes up to 48 hours after treatment with acid. The 20 hour sample was 
selected to determine the degradants as the retention time and area of the peaks in the 
chromatogram were consistent and was deemed the end of the degradation as a steady state 
was reached. 
 
Results and Discussion 
Chromatography and Product Ion Data of Omeprazole and 5-hydroxyomeprazole 
Using the conditions described previously, the retention time of omeprazole (Figure 1(A)) 
was 13.1 minutes (m/z =346.1266) and 5-hydroxyomeprazole (Figure 2(A)) was 11.0 
minutes (m/z = 362.1167).  
Having determined the retention time and precursor ion for both starting materials the 
product ion spectrum was also acquired using a collision energy of 40 eV. The measured m/z 
of the product ions formed from both omeprazole and 5-hydroxyomeprazole are described in 
Table 2 and a formula for each product ion is proposed. The mass measurement error was 
calculated from the experimental and theoretical data using Equation 1
18
.  
The product ions for omeprazole were in keeping with the literature values
19,20
. On 
comparing the product ions from omeprazole and 5-hydroxyomeprazole (Table 1) they were 
analogous, differing only by an O atom, with the exception of m/z = 136.0758 and 149.0709 
which are common to both precursor ions. The common product ions conform to the 
benzimidazole part of the molecule which is identical for both precursor ions. The mass 
measurement error for omeprazole and 5-hydroxyomeprazole product ions are < 3 ppm and 
are well within the recommended minimum of <10 ppm
18,21
 required for product ions. 
 
Chromatography and Accurate Mass of the Degradants in Acid Treated Omeprazole 
and 5-hydroxyomeprazole 
The instability of omeprazole and 5-hydroxyomeprazole was exploited and both were 
separately treated with 0.2 M HCl to accelerate their degradation. The chromatograms 
acquired, 20 hours after acid addition, were selected for elucidation. Their total ion 
chromatograms (TIC) in positive ion mode (m/z = 100 – 900) are shown in Figures 1(B) for 
omeprazole and 2(B) for 5-hydroxyomeprazole. 
The peak eluting at 13.1 minutes in the degraded omeprazole sample (Figure 1(B) has the 
same retention time as omeprazole. However, the isotope pattern for omeprazole comprised 
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of ions with m/z = 346.1219, 347.1252, 348.1176 and 349.1210. The degradation product at 
the same retention time has an isotope pattern with m/z = 345.1053, 345.6070, 346.1033 and 
346.6049 which is consistent with a doubly charged dimer ion, proving it is not omeprazole 
(Figure 3).  A false positive for omeprazole could result if the dimer isotope (m/z = 346.1033) 
is mistaken for omeprazole either by using an instrument of lower resolution or poor 
interpretation of the data. 
 
Rationale for Interpretation of MS Data 
ChemCalc software
22
 was used to generate possible formulae from the measured accurate 
mass of the unknown degradants. The degradants in the experiment are not totally unknown 
as the molecular structure of the starting material is already established
21
. The closest 
theoretical and measured accurate mass were compared taking in to consideration the atoms 
constituting the parent molecule. For example for omeprazole (Figure 1(A)) and 5-
hydroxyomeprazole (Figure 2 (A)) the imidazole and pyridine nitrogen atoms are likely to 
remain intact therefore the degradation products are likely to contain nitrogen atoms in 
multiples of three. Once the measured accurate mass of the precursor ions were determined, 
the product ion spectrum was acquired to obtain further structural information about the 
unknown degradants. The calculated mass measurement error for all the proposed formulae 
was < 2.1ppm (Table 2) which far surpasses the FDA guidelines
21
 of <5ppm for precursor 
ions. Based on the re-arrangement described by Brandstrom and Lindberg
23–26
 the unknown 
degradants can be determined and structures proposed. Consideration of the data indicates 
that monomer and dimer degradation products of omeprazole and 5-hydroxyomerazole 
formed and consist of singly and doubly charged ions.  
 
A+1 and A+2 Isotope Information 
The isotope pattern of an ion can give valuable information about the formula. (The most 








S isotopes is 
designated A+1 and the 
34
S cluster, with a lesser contribution from the other element 
isotopes, as A+2). The relative abundance of the A+1 isotope when compared to the main 
isotope can give an estimation of the number of carbon atoms in a molecule
27,28
. Measuring 
the abundance of the A+1 isotope to determine the number of C atoms in the molecule can 
prove inaccurate especially using ion trap instruments. Interferences can occur using ion trap 
instruments if too many ions are allowed into the trap at the same time. To limit the ion 
population inside the trap, there is a cut off for those of lower abundance such as the A+1 
isotopes. Therefore, in this case it is used to estimate the number of C atoms and distinguish 
between monomer and dimer ions
29
.  
The S atom also has a distinctive isotope pattern which aids interpretation of the HRMS data. 
The 
34
S isotope has an abundance of 4.52%, which is greater than the 
33
S isotope with an 
abundance of 0.8%. Omeprazole and 5-hydroxyomeprazole contain S and display this 
distinctive A+2 isotope pattern due mainly to sulphur. 
The experimental and theoretical isotope patterns are also compared including the mass shift 
between A and A+1 isotopes to establish if the ions are singly or doubly charged. In doubly 
charged ions the A+1 isotope differs by 0.5 u (nominal mass) instead of 1 u (nominal mass). 
Using the data described in Table 2, 5OH5 and 5OH3A both of which have very similar m/z 
are compared. 5OH5 has m/z = 346.1223 and the A+1 isotope is m/z = 347.1255. The 
abundance of the A+1 isotope is approximately 15% and the mass shift is 1 u (nominal mass). 
This ion is therefore singly charged and contains the correct A+1 isotope abundance for a 
molecule containing around 15 C atoms and in this case is consistent with a monomer ion. 
5OH3A has m/z = 345.1147 and the A+1 isotope is m/z = 345.6164. The abundance of the 
A+1 isotope this time is approximately 32% and the mass shift is 0.5 u (nominal mass). 
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Therefore this ion is doubly charged, contains over 30 C atoms and is consistent with a dimer 
ion.  
An unknown ion with m/z = 455.1419 was detected in the omeprazole degradation 
experiment and corresponded to a possible formula of C17H33N3O3S4. The A+1 isotope ratio 
was approximately 20% and the mass error was calculated as 4.3943 ppm which fit for the 
proposed formula. However, the A+2 isotope ratio was only 1.2% and does not conform to a 
substance containing 4 S atoms. This illustrates the importance of interpreting all of the 
isotope information.  
Using the measured accurate mass and isotope information structures for the most common 
degradants of omeprazole and 5-hydroxyomeprazole have been proposed and are described in 
Table 2. 
The similarity of the degradation products formed when omeprazole and 5-
hydroxyomeprazole were treated with 0.2 M HCL was notable. The precursor ion data for the 
acid degraded omeprazole and 5-hydroxyomeprazole differ by 1 O atom for monomer ions 
and 2 O atoms for dimer ions. For both omeprazole and 5-hydroxyomeprazole the main 
degradation product based on peak area was a re-arranged monomer (Table 2, OMEP5 and 
5OH5). Another monomer was also detected from both starting materials with no S atom 
(Table 2, OMEP1 and 5OH1), the low abundance of the A+2 isotope (1.5% and 1%) 
confirmed the absence of S atoms in the ion. Analogous singly and doubly charged dimer 
ions from both starting materials formed with between 1 and 3 S atoms in the bridge.  
The dimer ions with 2 S atoms in the bridge are easier to explain as these could be formed 
from 2 re-arranged molecules combining. However both starting materials produced a dimer 
ion with 3 S atoms in the bridge. One S atom has an exact mass of 31.9715 u and 2 O atoms 
31.9893 u. Since these values are so close it was necessary to confirm the ion contained 3 S 
atoms with 4 O atoms and not 2 S atoms with 6 O atoms. For example OMEP3B has an 
accurate mass of 689.2031. The formula for this was proposed as C34H37N6O4S3
+
 with an 
exact mass of 689.2033. If 1 S atom was swapped for 2 O atoms the formula would be 
C34H37N6O6S2
+ 
with an exact mass of 689.22105. The calculated mass measurement error 
would be -0.2902 ppm and -26.0439 ppm respectively, hence it is much more likely to be the 
formula with 3 S atoms. The abundance of the A+2 isotope is 15% which is in agreement 
with a molecule containing 3 S atoms. Structures OMEP1 and 5OH1 (Table 2) have both lost 
the S atom and this may be the source of the third S atom in the bridge. 
The multiple sulphur atoms in the bridge was unexpected. However, it can be explained given 
the affinity of the re-arranged omeprazole for the thiol on the target enzyme
3,23–26
. The 
proposed mechanism for dimer formation on acid treatment of omeprazole and 5-
hydroxyomeprazole is presented in Scheme 1.  
Product Ions of Omeprazole and 5-hydroxyomeprazole Degradation Products 
It has been established that the precursor ions for the degradation products of omeprazole and 
5-hydroxyomeprazole differ by either 1 or 2 O atoms for monomer and dimer ions 
respectively. The product ions for the degradation products of omeprazole and 5-
hydroxyomeprazole were acquired to determine if they too were analogous and had a mass 
shift equivalent to an O atom. These are reported in Table 3 and 4 respectively.  
 
Product Ions of Monomer Degradants 
Both omeprazole and 5-hydroxyomeprazole re-arranged to a main monomer degradation 
product (OMEP5 and 5OH5). The precursor and product ions had a mass shift equivalent to 




The product ions m/z = 297.1468 and m/z = 313.1413 (Tables 4 and 5) are unusual as they are 
radical cations containing an odd number of electrons. This was also observed for one of the 
product ions for omeprazole (m/z = 151.0992) and 5-hydroxyomeprazole (m/z = 167.0940) 
described in Table 1. The even electron rule states “even electron ions tend to form even 
electron product ions whereas odd electron ions tend to dissociate to form either odd or even 
electron ions” 30. Therefore the radical cations are in violation of this rule as they are from an 
even electron precursor ion. From the measured accurate mass data no other formula could be 
proposed except the radical cation. Violations to the even electron rule are known
30–32
 
especially in highly conjugated systems like omeprazole and 5-hydroxyomeprazole.  
 
Summary of Common Product Ions for Dimer Degradants in Acid Treated Omeprazole  
For the omeprazole degraded samples, the singly charged dimer precursor ions gave the same 
product ions regardless of the number of sulphur atoms in the sulphur bridge (Table 3). This 
was also observed for the singly charged dimer ions from 5-hydroxyomeprazole degradants 
which also gave the same product ions as each other but differed from omeprazole by an O 
atom. 
The product ion m/z = 149.0710 is common to both substrates which is indicative of the 
benzimidazole part of the molecule (Tables 3 and 4). This product ion is also observed in the 
product ion spectrum of omeprazole and 5-hydroxyomeprazole (Table 1) having no acid 
treatment. On comparing the product ion spectra of the degradation products, the product ions 
generated from the singly charged dimer ions are slightly different from the doubly charged 
equivalent, this is regardless of the number of sulphur atoms linking the dimers (Tables 3 and 
4). The doubly charged dimer ions from both substrates did not yield product ions at m/z = 
328.1108 and 295.1312 for omeprazole and 344.1058 and 311.1258 for 5-
hydroxyomeprazole. However the others described above were generated.  
 
Conclusion 
Although HRMS cannot unequivocally characterise the molecular structure of the 
degradation products of omeprazole and 5-hydroxyomeprazole in acid, accurate information 
about the elemental composition has been obtained. Coupled with the re-arrangement 
reported by Brandstrom credible molecular structures for the degradation products have been 
proposed for the first time, from the HRMS data as reported in this paper. This will in turn 
aid their identification in waste water and environmental locations. 
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Table 1. Predicted formulae for omeprazole and 5-hydroxyomeprazole product ions based on 
accurate mass data. The mass measurement error for each product ion has been calculated 
(Equation 1) and is less than 3 ppm. 



















 198.05833 198.0581 -1.16 C9H12NSO3
+
 214.05324 214.0531 -0.65 
C9H10NOS
+
 180.04776 180.0477 -0.33 C9H10NSO2
+
 196.04268 196.0425 -0.92 
C9H14NO2
+
















 149.07094 149.0707 -1.61 C8H9N2O
+
 149.07094 149.0709 -0.27 
C8H10NO
+
 136.07569 136.0757 0.07 C8H10NO
+























Table 2. Extracted ion data (positive ion mode) for the main precursor ions for acid degraded omeprazole and 5-hydroxyomeprazole. The 
accurate mass and exact mass for the A, A+1 and A+2 isotopes are described and the mass measurement error of the isotopes calculated. The 
approximate relative abundance of the A+1 and A+2 isotopes are also reported. Based on the molecular structures of the starting material, the 
formula determined from the accurate mass and the re-arrangement described by Brandstrom
(20, 21, 22, 23, 24)
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# The A+2 isotope cluster could not be completely resolved therefore, the accurate mass at the apex of the unresolved isotopes are reported and 





































   
282.1233 182.0609 149.0706 
OMEP2A 


































Product Ions (m/z) 
5OH5 Monomer  346.1223
+
 313.1413 
















   




   
298.1182 198.0579   
5OH7A 1 328.1205
2+


























error (ppm) = 
Accurate mass – Exact mass 
× 1000000 
  Exact mass   
 
Accurate mass = Measured mass. 




















Figure 1(A). Molecular structure and extracted ion chromatogram of omeprazole ((M+H)
+ 
 = 
346.1266). (B) Chromatogram of acid treated omeprazole showing retention time and 
measured accurate mass of degradants. (Positive ion mode using electrospray ionisation, scan 





















Figure 2(A). Molecular structure and extracted ion chromatogram of 5-hydroxyomeprazole 
((M+H)
+ 
 = 362.1167). (B). Chromatogram of acid treated 5-hydroxyomeprazole showing 
retention time and measured accurate mass of degradants. (Positive ion mode using 














Figure 3. Product ion spectra of the degradant and omeprazole which co-elute. The top 
spectrum is the dimer degradant with the proposed structure and the bottom is the spectrum 
for omeprazole. Potential interference could occur between the A+2 isotope of the degradant 





















Scheme 1. Proposed mechanism for monomer and dimer formation on acid treatment of 
omeprazole (H-S-R will be present in the acidic solution) and the enzyme block in the 
parietal cell (12). Based on the acid re-arrangement and mechanism of action for the drug on 
the target enzyme
3,23–26,33
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